Xeris Biopharma Holdings (XERS) Total Debt (2020 - 2026)

Xeris Biopharma Holdings' Total Debt history runs 7 years deep, the most recent figure standing at $221.2 million for Q1 2026.

• Quarterly Total Debt fell 8.48% year-over-year to $221.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $221.2 million (down 8.48% YoY) and the FY2025 annual result came in at $220.3 million, down 10.87% from the prior year.
• Total Debt was $221.2 million for Q1 2026 at Xeris Biopharma Holdings, roughly flat from $220.3 million in the prior quarter.
• Across five years, Total Debt topped out at $247.2 million in Q4 2024 and bottomed at $137.6 million in Q1 2022.
• A 5-year average of $204.1 million and a median of $218.6 million in 2025 frame the typical range for Total Debt.
• Annual changes were most pronounced in 2022 — Total Debt jumped 112.42% — and 2025, when it retreated 10.87%.
• Xeris Biopharma Holdings' Total Debt stood at $187.1 million in 2022, then advanced by 2.06% to $190.9 million in 2023, then increased by 29.48% to $247.2 million in 2024, then retreated by 10.87% to $220.3 million in 2025, then grew by 0.4% to $221.2 million in 2026.
• Business Quant data shows XERS's Total Debt at $221.2 million in Q1 2026, $220.3 million in Q4 2025, and $219.5 million in Q3 2025.